Drug
Maridebart Cafraglutide
Maridebart Cafraglutide: highest development phase Phase 3, developed by Amgen. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Maridebart cafraglutide NCT07871409 | Phase 3 | Obesity |
| Maridebart Cafraglutide NCT07037433 | Phase 3 | Atherosclerotic Cardiovascular Disease |
| Maridebart Cafraglutide NCT07575399 | Phase 3 | Obesity or Overweight |
| Maridebart cafraglutide NCT07866066 | Phase 3 | Diabetes Mellitus, Type 2 |
| Maridebart cafraglutide NCT07037459 | Phase 3 | Heart Failure With Preserved Ejection Fraction |
| Maridebart cafraglutide NCT07921316 | Phase 1 | Obesity |
| Maridebart cafraglutide NCT07908316 | Phase 1 | Obesity |
| Maridebart Cafraglutide NCT07832799 | Phase 1 | Overweight |
Latest
No recent events.
Follow Maridebart Cafraglutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.